Modafinil
Modafinil is a Schedule IV eugeroic that delivers small effects (Hedges g=0.10-0.12) on cognition in rested healthy adults per systematic reviews of healthy-subject cognitive enhancement, with larger benefits under sleep deprivation and a catastrophic-risk floor from SJS/TEN, eosinophilic myocarditis, and contested teratogenicity ([Onken 2024 ENTIS](https://onlinelibrary.wiley.com/doi/10.1111/acps.13643) n=150 found 2.0% major anomalies, contradicting Danish OR=2.7).
Modafinil scored 5.8 / 10 (👍 Worth trying) on the BioHarmony scale as a Substance → Pharmaceutical / Drug → Eugeroic (wakefulness agent).
What It Is
Modafinil is a wakefulness-promoting eugeroic pharmaceutical originally developed by Lafon Laboratories in France in the 1970s and approved by the FDA in 1998 under the trade name Provigil. Modafinil's labeled indications are narcolepsy, obstructive sleep apnea (as adjunct to CPAP), and shift-work sleep disorder. The molecule is a benzhydryl sulfinylacetamide and exists as a racemic mix of R-enantiomer (https://en.wikipedia.org/wiki/Armodafinil) and S-enantiomer; the R-isomer carries the longer half-life (12-15h vs ~4h for S) and most of the wakefulness-promoting activity.
Mechanistically, modafinil is an atypical dopamine transporter (DAT) inhibitor distinguishable from cocaine and amphetamines. Hersey and Tanda's 2023 work clarified that modafinil binds DAT in an occluded conformation (Ki=2.3 µM), versus cocaine's open-conformation binding, which explains modafinil's lower abuse liability and cleaner subjective profile. Modafinil also activates orexin neurons in the lateral hypothalamus, drives histaminergic wakefulness via orexin relay, elevates glutamate in hippocampus and striatum, reduces GABA in nucleus accumbens and globus pallidus, and shows an anti-neuroinflammatory profile uncommon among CNS stimulants.
The market history matters. Cephalon, modafinil's original US sponsor, paid $425M in 2008 to settle federal charges of off-label promotion to non-narcoleptic populations including ADHD, depression, and fatigue states for which modafinil was never approved. The FTC subsequently fined Cephalon $512M for pay-for-delay anticompetitive behavior with Teva and Mylan to delay generic entry. The European Medicines Agency in 2010 restricted modafinil's labeled use to narcolepsy only after concluding that for non-narcolepsy populations the risks outweigh the benefits, and after pediatric Stevens-Johnson syndrome and toxic epidermal necrolysis cases triggered a pediatric-use prohibition. Modafinil's "smart drug" reputation is therefore commercial overflow from an aggressive off-label marketing campaign that the regulators of multiple jurisdictions explicitly rebuked.
Terminology
- DAT: Dopamine transporter, the membrane protein that recycles dopamine from synaptic cleft back into the presynaptic neuron. Modafinil's primary molecular target.
- Eugeroic: Class of wakefulness-promoting agents distinct from classical CNS stimulants; modafinil and armodafinil are the prototypes.
- MWT: Maintenance of Wakefulness Test, the gold-standard objective measure of an individual's ability to stay awake under soporific conditions.
- ESS: Epworth Sleepiness Scale, an 8-item subjective questionnaire scored 0-24 measuring daytime sleepiness propensity.
- SJS/TEN: Stevens-Johnson syndrome and toxic epidermal necrolysis, life-threatening mucocutaneous reactions to drugs presenting with epidermal detachment; modafinil-associated cases are rare but FDA-acknowledged.
- CYP3A4: Cytochrome P450 3A4 isoenzyme, responsible for metabolizing roughly 50% of clinically used drugs. Modafinil induces CYP3A4 expression, accelerating ethinyl estradiol clearance.
- COMT: Catechol-O-methyltransferase, an enzyme degrading prefrontal dopamine. The Val158Met polymorphism (rs4680) creates Val/Val (high-activity, low baseline DA) and Met/Met (low-activity, high baseline DA) populations with differential response.
- FAERS: FDA Adverse Event Reporting System, the post-market pharmacovigilance database collecting spontaneous adverse-event reports.
- ENTIS: European Network of Teratology Information Services, a multinational consortium running prospective pregnancy-exposure cohorts.
- NAc: Nucleus accumbens, the ventral striatum region central to reward processing where modafinil reduces GABA tone.
- Hedges g: An effect-size statistic similar to Cohen's d but corrected for small-sample bias; conventional anchors: 0.2 small, 0.5 medium, 0.8 large.
- AUC: Area under the plasma concentration-time curve, a measure of total drug exposure.
How this score is calculated →
Upside (2.20 / 5.00)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Efficacy | 25% | 3.6 | 0.900 | |
| Breadth of Benefits | 15% | 2.8 | 0.420 | |
| Evidence Quality | 25% | 3.5 | 0.875 | |
| Speed of Onset | 10% | 4.5 | 0.450 | |
| Durability | 10% | 1.5 | 0.150 | |
| Bioindividuality Upside | 15% | 2.7 | 0.405 | |
| Total | 3.200 |
Upside Rationale
Efficacy (3.6/5.0)
Modafinil's efficacy is bimodal by population. In rested healthy adults, Battleday and Brem's 2015 systematic review of 24 RCTs found a small overall effect size (Hedges g≈0.10-0.12) on attention and executive function, corroborated by meta-analyses meta showing g≈0.10 across the cognitive enhancement literature. In sleep-deprived adults, however, modafinil produces moderate-to-large benefits on reaction time, vigilance, and complex task performance per military aviator studies (military aviator trials, 64-hour wake) and Caldwell 1995. For the FDA-labeled population (narcolepsy/OSA), the Cochrane 2010 meta documented MWT improvements of MD +3.56 minutes (95% CI 2.25-4.86) and Epworth Sleepiness Scale reductions of MD -3.34 to -4.5 points, both clinically meaningful. The 3.6 score reflects Nick's actual use case (sleep-debt rescue, travel) plus narcolepsy efficacy averaged with the small healthy-rested signal.
Breadth of Benefits (2.8/5.0)
Modafinil's breadth is narrow. Modafinil's effects concentrate on wakefulness, attention, vigilance, executive function, and reaction time. Modafinil shows secondary mood elevation in MS-fatigue and depression-adjunct trials but Cochrane's 2019 schizophrenia review found no consistent cognitive benefit. Modafinil produces no documented effects on body composition, longevity biomarkers, inflammation (despite an anti-neuroinflammatory mechanistic profile), cardiovascular endpoints, hormonal function, or peripheral metabolic markers. Mohamed 2016 found modafinil reduced divergent creativity, and Müller 2013 corroborated a non-verbal cognition signal that suggests modafinil narrows rather than broadens cognitive output. The 2.8 score reflects modafinil's CNS-only narrow-but-real action profile, not the systemic whole-body breadth of interventions like exercise, sleep, or polyphenols.
Evidence Quality (3.5/5.0)
Modafinil's evidence base spans roughly 100 RCTs across narcolepsy, OSA, shift-work disorder, ADHD, MS fatigue, depression-adjunct, schizophrenia cognition, and cocaine-use disorder. Ten major meta-analyses are catalogued including Cochrane 2010 narcolepsy, Cochrane 2019 schizophrenia, Battleday and Brem 2015 healthy cognition, meta-analyses, an MS-fatigue meta-analysis MS fatigue, Jung 2026 condition-specific AEs, and an updated 2026 narcolepsy meta noting zero new RCTs in the past decade. Industry funding penalty applies (-0.5) given Cephalon's role in early trial design. The Onken 2024 ENTIS prospective cohort vs Danish-cohort observational data Danish cohort produces an unresolved teratogenicity contradiction. No independent replication of cognitive-enhancement endpoints. Evidence is sufficient but stale and contradictory in critical safety domains. Score reflects high quantity, moderate independence, contested key safety findings.
Speed of Onset (4.5/5.0)
Modafinil's onset is rapid and reliable. Per multiple PK trials and Nick's own observation, first effects emerge at approximately 30 minutes post-oral-dose, full subjective wakefulness lands at 45-60 minutes, and peak plasma concentration is 2-4 hours. Duration of action runs 8-15 hours dose-dependent, driven by the R-modafinil isomer's 12-15 hour plasma half-life. The pharmacokinetic profile is sex-specific: women clear modafinil approximately 30% slower with Cmax approximately 24% higher per pharmacokinetic data, which justifies lower starting doses in female users. Modafinil produces effects significantly faster than most chronic-use cognitive interventions (creatine, lion's mane, omega-3) but slower than fast-onset stimulants like caffeine (15-20 minutes) or amphetamines (15-30 minutes). Score reflects the consistent within-an-hour onset.
Durability (1.5/5.0)
Modafinil produces zero carryover benefit beyond the dosing window. Effects begin to wane as plasma levels drop below threshold, with most users reporting a return to baseline 12-18 hours post-dose and a residual mild fatigue rebound the day after a high-dose use. There is no neuroadaptation, no protocol-driven adaptation, no enduring benefit, and no mechanism by which modafinil would produce durable structural or neurochemical changes after washout. The drug works only while it is on board. Compare to creatine monohydrate (saturation produces sustained intramuscular benefit even after stopping for 4-6 weeks) or chronic exercise (cardiorespiratory adaptations persist months). The 1.5 score reflects modafinil being a strict on-while-dosing pharmacological agent with no built-in durability mechanism.
Bioindividuality (2.7/5.0)
Modafinil's response varies sharply by genotype and baseline cognition. COMT genotype work demonstrated COMT Val/Val homozygotes are robust modafinil responders while Met/Met homozygotes are partial non-responders, hypothesized to reflect baseline prefrontal dopamine tone. Van Cutsem 2025 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12507762/) nuances the picture with reaction-time response varying by single-nucleotide polymorphism (A/A 79±51ms improvement vs G/A 13±13ms) and intra-individual response stability ICC=0.90, while concluding the genetic basis is complex and cannot be reduced to one polymorphism. early modafinil cognition trials IQ stratification found benefit at IQ ~106 but not at IQ ~115, which is directly relevant to the typical biohacker target audience. Sex-specific PK favors lower female dosing. Score reflects substantial responder heterogeneity that makes modafinil hit-or-miss by individual.
Downside (2.25 / 5.00)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Safety Risk | 30% | 4.0 | 1.200 | |
| Side Effect Profile | 15% | 2.8 | 0.420 | |
| Financial Cost | 5% | 2.5 | 0.125 | |
| Time/Effort Burden | 5% | 1.3 | 0.065 | |
| Opportunity Cost | 5% | 2.5 | 0.125 | |
| Dependency / Withdrawal | 15% | 2.3 | 0.345 | |
| Reversibility | 25% | 1.5 | 0.375 | |
| Total | 2.655 | |||
| Harm subtotal × 1.4 | 3.276 | |||
| Opportunity subtotal × 1.0 | 0.315 | |||
| Combined downside | 3.591 | |||
| Baseline offset (constant) | −1.340 | |||
| Effective downside penalty | 2.251 |
Downside Rationale
Safety Risk (4.0/5.0)
Modafinil's catastrophic-risk floor is set by four intrinsic signals. First, Stevens-Johnson syndrome and toxic epidermal necrolysis cases in pediatric trials triggered an EMA pediatric prohibition and an FDA boxed warning. Second, the 2025 FAERS systematic study (real-world Q1 2004 to Q1 2024 pharmacovigilance) added eosinophilic myocarditis as an unlabeled signal with median onset 76.5 days. Third, MAOI hypertensive crisis case reports document a serious drug-interaction risk. Fourth, teratogenicity is contested: Danish-cohort observational data Danish cohort (n=49) reported 12% major malformation rate with OR 2.7, while Onken 2024 ENTIS multicenter prospective cohort (n=150) found 2.0% major anomalies, NOT statistically elevated vs background. Per BioHarmony Rule 1, multiple distinct catastrophic signals justify the 4.0 floor; Nick's intermittent low-dose protocol does not eliminate the population-level signal.
Side Effects (2.8/5.0)
The non-catastrophic AE tail is real but generally mild-to-moderate at off-label intermittent doses. Jung 2026 condition-specific meta documented insomnia RR 4.97 in ADHD off-label use and decreased appetite RR 4.21. Common AEs across populations include headache (15-30%), nausea (10-15%), anxiety (5-15%), nervousness, dry mouth, and bruxism (community surveys report 50%+ at 200 mg doses, mitigated by the canonical magnesium glycinate 400 mg + alpha-GPC 300-600 mg stack). Long-term healthy-user reports cite anhedonia development as a retirement signal driving multi-year users to discontinue. Nick reports caffeine potentiation, distraction-lock, and slight urinary scent changes at 25-50 mg. The 2.8 score reflects intermittent-use side effect burden; chronic 200 mg daily would push this to 3.5.
Financial Cost (2.5/5.0)
Modafinil's accessible cost is modest at the most realistic channels. Generic modafinil via insurance for narcolepsy/OSA runs $30-50/month at standard 200 mg daily dosing. Off-label users source from gray-market vendors (ModafinilXL, BuyModa) shipping Modalert and Modvigil from Indian generics manufacturers, with per-pill costs of $0.80-2.50 at 50-pill volume; Nick's 2-3x/month protocol translates to roughly $5-10/month equivalent. Per BioHarmony Rule 4, score the most accessible legitimate channel: gray-market sourcing of WHO-prequalified Indian generics is the channel most off-label users actually use. The 2.5 score reflects modest cost not approaching the $200+/month threshold for a 5.0, but with implicit legal/sourcing exposure that puts modafinil above zero-cost interventions.
Time/Effort Burden (1.3/5.0)
Modafinil's effort burden is trivial. A single oral dose, swallowed with water, anywhere from 25 mg to 200 mg, taken once before 10:00 AM to avoid sleep disruption per Nick's hard-rule observation. No injection, no compounding, no protocol stacking required (though community standard adds magnesium glycinate 400 mg + alpha-GPC 300-600 mg for bruxism mitigation). Cycling 2-3x per week is the experienced-user consensus to prevent tolerance and anhedonia. No shopping logistics beyond the prescription pickup or international vendor order. Compare with peptide injections (subcutaneous protocol, sterile reconstitution, refrigeration), red-light therapy (10-20 minute device session), or exercise protocols (60+ minute commitment). The 1.3 score reflects oral pharmaceutical's near-zero-effort delivery profile with the only effort being timing discipline.
Opportunity Cost (2.5/5.0)
Modafinil's opportunity cost is modest but non-zero. Late dosing (after 10:00 AM per Nick's rule, after 12:00 PM per community consensus) materially disrupts sleep architecture, with REM suppression and sleep-onset latency increases documented in PK trials. Modafinil can mask sleep debt rather than resolve it, leading to compounding sleep deficit if used as a chronic substitute for adequate rest. Mohamed 2016 reduced divergent creativity is a meaningful opportunity cost for creative professionals. The chronic-use anhedonia signal in long-term healthy users is the steepest opportunity cost on long timelines. Modafinil also crowds out lifestyle-first interventions (sleep hygiene, exercise, nutrition) when used as a workaround. The 2.5 score reflects these moderate trade-offs at intermittent use; chronic daily use would push to 3.5.
Dependency (2.3/5.0)
Modafinil's dependency is functional and psychological, not classical addiction. Modafinil's atypical DAT binding gives it materially lower abuse liability than amphetamines or cocaine, with lower euphoria and lower self-administration in animal models. However, tolerance does develop with regular use, with experienced users reporting 200 mg doses no longer producing the original effect after 2-3 months of daily use, requiring cycling or dose escalation. Withdrawal-fatigue rebound is reliably reported the day after a use, particularly at 200 mg+ doses. Long-term healthy users describe psychological reliance and a "won't function without it" pattern that meets BioHarmony's functional-dependency criterion (3.5-4.0 range) at chronic use, but Nick's 2-3x/month intermittent pattern stays below the rebound threshold. Score 2.3 averages intermittent-use functional reliance with chronic-use rebound risk.
Reversibility (1.5/5.0)
Modafinil is fully reversible pharmacologically. The R-isomer's 12-15 hour half-life translates to roughly 60-75 hours (5 half-lives) for complete plasma washout, and effects fully return to baseline within 24-48 hours of discontinuation in intermittent users. There is no neurotoxicity signal at therapeutic doses, no documented permanent receptor downregulation, and no structural brain changes in human imaging studies of long-term users. The chronic-use anhedonia signal is the one durability question. Long-term healthy users report a multi-week recovery period after stopping, but the recovery is consistently reported as complete. Long-term healthy-user data is essentially zero, which is the single biggest unresolved question on this dimension; if multi-decade chronic use produced subtle receptor changes, the literature would not yet have detected it. Score 1.5 reflects strong washout pharmacology with explicit acknowledgment of the long-term-data gap.
"For the indications studied, the benefits of modafinil do not outweigh its risks, except in narcolepsy." European Medicines Agency, 2010 review of modafinil-containing medicines
Verdict
✅ Best for:
Modafinil is best for diagnosed narcolepsy and OSA patients (https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003724.pub3/full), shift-work sleep disorder patients managing inverted circadian schedules, MS-fatigue patients per an MS-fatigue meta-analysis meta, and selective off-label users running an intermittent travel-rescue or sleep-debt-rescue protocol like Nick's 25-50 mg, 2-3x/month pattern. Modafinil is best for COMT Val/Val genotype responders , for adults with IQ closer to ~106 than ~115 per early modafinil cognition trials, and for use cases where rapid wakefulness onset (30-45 minutes) is the primary requirement. Modafinil pairs well with magnesium glycinate 400 mg, alpha-GPC 300-600 mg, and disciplined pre-10:00-AM timing. Modafinil is NOT best for chronic daily off-label cognitive enhancement.
❌ Avoid if:
Avoid modafinil if pregnant or planning pregnancy (Danish-cohort observational data OR=2.7 vs Onken 2024 2.0%, the contradiction means uncertainty, not safety), if on oral contraceptives without backup contraception (CYP3A4 induction reduces ethinyl estradiol AUC -18%), if on MAOIs (hypertensive crisis case reports), if you have a personal or family history of Stevens-Johnson syndrome / toxic epidermal necrolysis or known sulfa allergy, if you have a history of psychiatric illness particularly mania or psychosis, if you have a known cardiac arrhythmia or LVH, or if you cannot reliably dose before 10:00 AM. Avoid chronic daily off-label use given the anhedonia retirement signal in long-term healthy users and the absence of long-term data. Avoid sourcing from unverified gray-market vendors. Avoid in pediatric populations (EMA prohibition).
Use Case Breakdown
The overall BioHarmony score reflects the intervention's primary evidence profile. These subratings are independent assessments per use case.
| Use Case | Score | Summary |
|---|---|---|
| 👍 Cognition / Focus Primary | 6.5 | Modafinil cognition effects depend on baseline state. In rested healthy adults, Battleday and Brem 2015 systematic review of 24 RCTs found Hedges g=0.10-0.12 across attention and executive function endpoints, a small effect that most users won't reliably notice. In sleep-deprived adults, modafinil produces moderate-to-large benefits per military aviator studies military aviator trials. The COMT Val/Val genotype responder pattern and early modafinil cognition trials IQ stratification (benefit at IQ ~106, none at ~115) mean cognition benefit is bimodal. Mohamed 2016 reduced divergent creativity is a real cognitive trade-off. |
| 💪 Energy / Fatigue Primary | 7.0 | Modafinil energy use case is its strongest. The 8-15 hour wakefulness window driven by the R-modafinil 12-15 hour half-life delivers reliable, clean-feeling energy without jitters, vasoconstriction, or post-dose crash characteristic of amphetamines or high-dose caffeine. The atypical DAT-binding profile underlies the cleaner subjective signature versus open-conformation DAT inhibitors. Modafinil is the most reliable single-dose all-day energy intervention in the eugeroic class, with the caveat that morning-only timing (before 10 a.m.) is non-negotiable for sleep preservation. |
| ⚖️ Mood / Emotional Regulation Primary | 5.5 | Modafinil produces mild mood elevation in MS-fatigue and treatment-resistant depression as adjunct. Mechanism likely involves mild dopaminergic action plus indirect mood benefit of restored wakefulness in fatigued populations. Modafinil is NOT a primary antidepressant. The chronic-use anhedonia signal documented in long-term healthy users (Vice 'love work hate people' canonical narrative, r/Nootropics retirement reports) is a meaningful long-term mood downside. Score reflects modest acute mood elevation in some populations balanced against chronic-use anhedonia risk that is the leading retirement reason among multi-year off-label users. |
| ⚖️ Memory Primary | 5.5 | Modafinil memory effects are modest and state-dependent. Working memory benefit is documented in sleep-deprived adults and partially in rested healthy adults (https://pubmed.ncbi.nlm.nih.gov/26381811/). Long-term declarative memory and consolidation effects are minimal in healthy populations. In schizophrenia populations, Cochrane 2019 review found no consistent cognitive benefit. Score reflects modest acute working-memory enhancement in fatigued or low-baseline populations, with the caveat that the Mohamed 2016 reduced divergent creativity finding suggests modafinil narrows rather than broadens cognitive output. |
| 👍 Reaction Time / Coordination | 6.5 | Modafinil reaction-time effects are well-documented under sleep deprivation. military aviator studies military aviator trials demonstrated modafinil restored 64-hour-wake reaction-time performance to near-rested baseline. Van Cutsem 2025 documented genotype-stratified reaction-time response (A/A 79±51ms improvement vs G/A 13±13ms, ICC=0.90 trait-stable). In rested healthy adults, reaction-time benefit is modest. Score reflects strong acute reaction-time benefit in sleep-deprived populations with substantial bioindividual variance and minimal benefit at rested baseline. |
| ⚖️ Flow State / Peak Mental Performance | 5.5 | Modafinil flow-state effects are mixed. The narrow attention-lock and 8-15 hour wakefulness window can support sustained focus on convergent tasks where flow is linked to high-arousal-narrow-attention. However, the distraction-lock subjective profile can override flexible attention reallocation that flow requires. The Csikszentmihalyi flow construct emphasizes balance between challenge and skill plus flexible attention, which modafinil's narrowed beam does not enhance. For high-output convergent narrow tasks (coding, deep technical work), modafinil supports focus; for flexible-attention flow states (sport, music, conversation), modafinil's narrowing may actually impair flow. |
| ⚖️ Depression | 5.0 | Modafinil depression-adjunct effects have small RCT support in treatment-resistant depression and bipolar depression. Mechanism (mild dopaminergic action, orexin-mediated arousal restoration) is plausible for the energy-fatigue dimension of depression. an MS-fatigue meta-analysis meta on MS-fatigue documented mood improvement as secondary endpoint. Modafinil is NOT a primary antidepressant and chronic daily use carries the anhedonia retirement signal. Score reflects modest adjunctive utility in fatigue-predominant depression with explicit acknowledgment that primary antidepressant pharmacotherapy and lifestyle intervention should be optimized first. |
| ○ Endurance / Cardio | 4.5 | Modafinil endurance-cardio effects are state-dependent. In sleep-deprived athletes, modafinil restores reaction-time and vigilance, which translates to better endurance-task performance per Killgore-class trials. In rested healthy athletes, no direct VO2 max or time-trial improvements have been demonstrated. WADA prohibits modafinil in competition under the S6 stimulants class; competitive athletes face career-ending consequences. Mild ergogenic effect under sleep deprivation does not translate to well-rested baseline performance. Not first-line for endurance enhancement; targeted training, sleep, and nutrition return more endpoint-per-dollar. |
| ○ Anxiety | 3.5 | Modafinil anxiety profile is net negative. Anxiety is reported as a side effect in 5-15% of users at off-label doses. The COMT Val/Val responder pattern overlaps with high-anxiety phenotypes, meaning users predisposed to anxiety may experience amplification rather than relief. Sympathetic activation, increased heart rate, and bruxism (50%+ at 200 mg) are common autonomic signals. Modafinil is contraindicated for users with documented anxiety disorders or panic disorder. For anxiety as primary indication, modafinil is the wrong tool; CBT, lifestyle, and targeted pharmacotherapy are first-line. |
| ○ Stress / Resilience | 3.0 | Modafinil stress-resilience effects are limited. Anxiety is reported as a side effect in 5-15% of users at off-label doses, not as a benefit. Mild dopaminergic action and orexin-mediated wakefulness do not directly engage HPA axis modulation or vagal tone. Some users with depressive-fatigue spectrum experience indirect stress-resilience improvement via energy restoration, but modafinil is not anxiolytic. Bruxism (50%+ at 200 mg per community surveys) is a stress-system sympathetic-dominance signal. Adaptogens and exercise return more stress-resilience-per-dollar than modafinil for primary stress presentations. |
| ○ Creativity / Divergent Thinking | 3.0 | Modafinil creativity effects are net negative for divergent thinking. Mohamed 2016 documented reduced divergent creativity, and Müller 2013 corroborated a non-verbal cognition signal that suggests modafinil narrows rather than broadens cognitive output. The distraction-lock subjective profile (Nick reports 'lasered into that distraction for long periods of time') reinforces the convergent-thinking bias. For convergent narrow-task work, modafinil is helpful; for synthesis, ideation, and creative-problem-solving work, modafinil is the wrong tool. Creative professionals seeking enhancement should look to caffeine or psilocybin micro-protocols rather than modafinil. |
| ○ Geriatric / Aging Population | 3.0 | Modafinil geriatric use requires reduced clearance considerations and lower starting doses. Hepatic metabolism slows with age, and modafinil's CYP-mediated drug interactions become more clinically significant in polypharmacy populations common in older adults. SJS/TEN risk and contested teratogenicity are not relevant in geriatric populations, but cardiovascular risks (mild BP/HR elevation) are more consequential. Score reflects modest off-label utility in geriatric narcolepsy and OSA-adjunct populations with explicit dose-reduction protocols, but generalized geriatric cognitive enhancement is not supported by evidence. |
| ○ Anti-Inflammatory | 3.0 | Modafinil shows anti-neuroinflammatory profile uncommon among CNS stimulants per preclinical neurochemistry work mechanistic review. Pre-clinical data suggests modulation of microglial activation and central cytokine production, but human anti-inflammatory endpoint data (CRP, IL-6, TNF-α) is essentially absent. The mechanism is interesting but does not translate to a clinical anti-inflammatory indication. Users with inflammatory conditions seeking anti-inflammatory intervention should look to dietary intervention, omega-3, and targeted pharmacotherapy. Score reflects mechanistic interest without clinical endpoint translation. |
Frequently Asked Questions
Does modafinil actually work for cognitive enhancement?
Modafinil produces small effects (Hedges g=0.10-0.12) on cognition in rested healthy adults per Battleday and Brem's 2015 systematic review of 24 RCTs and Kredlow's meta-analysis. In sleep-deprived adults, modafinil produces moderate-to-large benefits on reaction time, vigilance, and complex task performance per military aviator studies military aviator trials, where 64-hour-wake performance was restored to near-rested baseline. The catch: modafinil's cognitive benefit in rested healthy adults is bimodal by COMT genotype and IQ-stratified . For most biohacker audiences, modafinil works best as a sleep-deprivation rescue tool rather than a daily cognitive enhancer. Mohamed 2016 also documented reduced divergent creativity, which means modafinil narrows rather than broadens cognitive output.
Is modafinil safe long-term?
Modafinil's long-term safety in healthy off-label users is essentially uncharacterized. The updated narcolepsy meta documented zero new RCTs in the past decade, and all efficacy and safety data come from 1990s-early 2000s narcolepsy populations. Known long-term concerns include the chronic-use anhedonia signal that drives multi-year users to retire (https://www.vice.com/en/article/are-smart-drugs-driving-a-silicon-valley-productivity-boom/), tolerance development requiring dose escalation or cycling, and the FAERS surveillance identifying eosinophilic myocarditis as an unlabeled signal with median onset 76.5 days. The teratogenicity question is contested between Danish-cohort observational data (12% major malformation rate, OR 2.7) and Onken 2024 ENTIS (2.0% major anomalies, not statistically elevated). For chronic daily off-label use, the evidence simply does not exist to support claims of safety.
What's the best modafinil dose for productivity?
Community consensus shifted from 200 mg to 100 mg as the cognitive-enhancement standard dose in recent years, with experienced users reporting 100 mg delivers most of the benefit with materially fewer side effects. Nick uses 25-50 mg, 2-3x per month, on travel and sleep-debt rescue days. The FDA-labeled 200 mg daily dose was set for narcolepsy patients with severe excessive daytime sleepiness, not for cognitive enhancement in rested healthy adults. Cycling 2-3x per week is the canonical experienced-user pattern to prevent tolerance and anhedonia. Women clear modafinil ~30% slower with Cmax ~24% higher per pharmacokinetic data, justifying lower starting doses. The community-standard stack adds magnesium glycinate 400 mg for bruxism mitigation and alpha-GPC 300-600 mg for choline support. Take before 10:00 AM to preserve sleep architecture.
How long does modafinil take to kick in?
Modafinil's onset is rapid and reliable. First effects emerge at approximately 30 minutes post-oral-dose, full subjective wakefulness lands at 45-60 minutes, and peak plasma concentration occurs at 2-4 hours. The duration of subjective wakefulness runs 8-15 hours dose-dependent. Nick reports "I start to feel it within about 30 minutes and it comes on fully within about 45." Compared to other interventions: caffeine kicks in at 15-20 minutes, amphetamines at 15-30 minutes (or immediately for IR formulations), and most chronic-use cognitive supplements (creatine, omega-3, lion's mane) take weeks of consistent dosing. Modafinil's R-isomer 12-15 hour half-life means a single morning dose can disrupt that night's sleep, which is why the before-10:00-AM rule is non-negotiable. Onset can be delayed by food, particularly high-fat meals.
What are modafinil's worst side effects?
Modafinil's catastrophic-risk floor is set by Stevens-Johnson syndrome and toxic epidermal necrolysis (FDA boxed warning, EMA pediatric prohibition), eosinophilic myocarditis (FAERS surveillance, median onset 76.5 days), MAOI hypertensive crisis case reports, and contested teratogenicity (Danish-cohort observational data OR 2.7 vs Onken 2024 2.0% major anomalies). The non-catastrophic AE tail at off-label intermittent doses includes insomnia (https://pubmed.ncbi.nlm.nih.gov/41367108/), decreased appetite (RR 4.21), headache (15-30%), nausea (10-15%), anxiety (5-15%), bruxism (50%+ at 200 mg per community surveys, mitigated by magnesium glycinate 400 mg), and the chronic-use anhedonia retirement signal. Nick reports caffeine potentiation, distraction-lock, and slight urinary scent changes at 25-50 mg. Severity scales with dose and duration; intermittent low-dose use is materially safer.
Modafinil vs armodafinil: which is better?
Armodafinil (Nuvigil) is the pure R-enantiomer of modafinil; modafinil (Provigil) is the racemic mix of R and S. Armodafinil's longer half-life (~15 hours vs ~10-12 for racemic modafinil) produces a more sustained wakefulness window but a higher likelihood of disrupting that night's sleep. Nick reports: "People sometimes use or prefer armodafinil instead, but it's more expensive and gives me headaches. It's also less balanced than some of the alternative nootropic formulas." Cost: armodafinil is materially more expensive even via gray-market generics (Waklert, Artvigil) than modafinil generics (Modalert, Modvigil). Subjective profile reports are mixed: some users prefer armodafinil's smoother onset, others find armodafinil more headache-inducing per Nick's experience. For most off-label users at intermittent doses, racemic modafinil at 50-100 mg is the better starting point.
Will modafinil show up on a drug test?
Standard 5-panel and 10-panel workplace drug tests do NOT screen for modafinil. Modafinil is not chemically related to amphetamines, cocaine, opioids, benzodiazepines, or cannabinoids, and standard immunoassay screens do not produce false positives for those classes. However, specialized tests can detect modafinil, including expanded sport drug-testing panels. WADA (World Anti-Doping Agency) explicitly prohibits modafinil in competition under the S6 stimulants class. Modafinil's plasma half-life is 12-15 hours (R-isomer), and modafinil metabolites (modafinil acid, modafinil sulfone) are detectable in urine for 2-3 days post-dose. Off-label users in regulated industries (military, aviation, transportation, competitive sport) face career-ending consequences if tested positive. Schedule IV prescription status means a valid prescription provides legal protection in most US workplace contexts.
Is modafinil safe during pregnancy?
Modafinil's pregnancy safety is contested. Danish-cohort observational data Danish national cohort (https://pubmed.ncbi.nlm.nih.gov/31990303/) reported a 12% major malformation rate with OR 2.7, which triggered FDA pregnancy-category D labeling and EMA contraindication updates. However, Onken 2024 ENTIS multicenter prospective cohort (DOI 10.1111/acps.13643, n=150 first-trimester exposures across 18 services in 12 countries) found 2.0% major congenital anomalies, NOT statistically elevated versus background population rate. The contradiction reflects differences in cohort design, exposure ascertainment, and indication selection bias; the question is unresolved. The bidirectional contraceptive interaction matters: modafinil reduces ethinyl estradiol AUC by 18% via CYP3A4 induction, so women on oral contraceptives must use backup contraception during modafinil use and for 1 month after. Conservative recommendation: avoid modafinil during pregnancy and planned conception until the contradiction resolves.
How This Score Could Change
BioHarmony scores are living assessments. New research, regulatory changes, or personal context can shift the score up or down. These are the most likely scenarios that would change this intervention's rating.
| Scenario | Dimensions Affected | New Score | Tier |
|---|---|---|---|
| New independent RCT replicates Onken 2024 prenatal safety (n=300+, low malformation rate) | Safety 4.0→3.2, Evidence 3.5→4.0 | 6.7 / 10 | 👍 Worth trying |
| Long-term healthy-user RCT (>5 years) shows anhedonia + tolerance signal | Side Effects 2.8→3.8, Dependency 2.3→3.3, Reversibility 1.5→2.5 | 4.5 / 10 | ⚠️ Caution |
| New head-to-head RCT vs amphetamine + caffeine in cognitive enhancement shows superiority | Efficacy 3.6→4.2, Evidence 3.5→4.0 | 6.4 / 10 | 👍 Worth trying |
| FDA SJS/TEN signal expands to adult population requiring boxed warning escalation | Safety 4.0→4.5, Side Effects 2.8→3.5 | 4.8 / 10 | ⚖️ Neutral |
| Cochrane systematic review of healthy-adult cognitive enhancement concludes no clinical benefit | Efficacy 3.6→2.5, Evidence 3.5→3.0 | 4.7 / 10 | ⚠️ Caution |
Key Evidence Sources
- Battleday RM, Brem AK. (2015). Modafinil for cognitive neuroenhancement in healthy non-sleep-deprived subjects: a systematic review. European Neuropsychopharmacology. . Note: Systematic review of 24 RCTs in healthy rested adults; Hedges g=0.10-0.12 overall, larger benefit on more complex executive-function tasks
- Damgaard-Mørch NL et al. (2020). Use of modafinil during pregnancy and risk of major congenital malformations. JAMA. PMID 31990303. . Note: Danish national cohort, n=49 first-trimester exposures, 12% major malformation rate, OR 2.7. Triggered FDA labeling update
- Onken M et al. (2024). Pregnancy outcomes after first-trimester exposure to modafinil: A multicenter prospective cohort study. Acta Psychiatrica Scandinavica. DOI 10.1111/acps.13643. Note: ENTIS prospective cohort, n=150 first-trimester exposures across 18 services in 12 countries; 2.0% major congenital anomalies, NOT statistically elevated versus background. Contradicts Danish-cohort observational data.
- Jung J et al. (2026). Condition-specific adverse events of modafinil: a systematic review and meta-analysis. PMID 41367108. Note: Off-label condition-stratified AE meta; ADHD off-label insomnia RR 4.97, decreased appetite RR 4.21.
- Van Cutsem J et al. (2025). Modafinil response stability and metacognitive impairment under sleep deprivation. PMC12507762. Note: Reaction-time response by SNP (A/A 79±51ms, G/A 13±13ms); intra-individual response stability ICC=0.90; metacognitive impairment under sleep deprivation.
- Mohamed AD. (2016). The effects of modafinil on convergent and divergent thinking of creativity. Journal of Creative Behavior. Note: Reduced divergent creativity finding; modafinil narrows rather than broadens cognitive output.
- Müller U et al. (2013). Effects of modafinil on non-verbal cognition, task enjoyment and creative thinking in healthy volunteers. Neuropharmacology. . Note: Corroborates Mohamed 2016 non-verbal cognition signal
- Cochrane Collaboration. (2019). Modafinil for the cognitive deficits associated with schizophrenia.. Note: Independent Cochrane review found no consistent cognitive benefit in schizophrenia.
Other interventions for Cognition & Focus
See all ratings →📊 How BioHarmony scoring works
BioHarmony translates a weighted expected-value calculation into a reader-facing 0–10 score. 5.0 is neutral (benefits and risks balance). Above 5 = benefits outweigh risks; below 5 = risks outweigh benefits.
Harm-type downsides (safety risk, side effects, reversibility, dependency) carry a 1.4× precautionary multiplier. Harm weighs more than benefit. Opportunity-type downsides (financial cost, time/effort, opportunity cost) are subtracted at face value.
Use case subratings are independent assessments of how well the intervention addresses specific health goals. They are not components of the overall score. Each subrating reflects the scorer's judgment based on use-case-specific evidence, safety, and effect sizes.
Every dimension is evaluated on a 1–5 scale, and the baseline (1) is subtracted before weighting. A perfect intervention with zero downsides contributes zero penalty rather than a residual floor, so top-tier scores are actually reachable.
EV = Upside − Downside
EV = 2.200 − 2.250 = -0.050
EV ranges from −5 to +5. Adding 7 shifts to 2–12, dividing by 12 normalizes to 0–1, then ×10 gives the 0–10 score.
Score = ((-0.050 + 7) / 12) × 10 = 5.8 / 10
